Explore the dynamic landscape of metastatic non-squamous non-small cell lung cancer treatment, focusing on molecular genotyping, targeted therapies, and the evolving standard of care.
Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.